

Jonas Wetter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5705817/publications.pdf>

Version: 2024-02-01

68
papers

1,620
citations

318942

23
h-index

371746

37
g-index

70
all docs

70
docs citations

70
times ranked

2409
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement <i>C4</i> Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2022, 74, 1440-1450.	2.9	17
2	Extramucosal Formation and Prognostic Value of Secretory Antibodies in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 801-809.	2.9	4
3	Variation of Complement Protein Levels in Maternal Plasma and Umbilical Cord Blood during Normal Pregnancy: An Observational Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3611.	1.0	1
4	Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	9
5	Circulating anti-citrullinated protein antibodies containing secretory component are prognostic for arthritis onset in at-risk patients. <i>Clinical and Experimental Immunology</i> , 2021, 204, 344-351.	1.1	4
6	Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus. <i>Lupus</i> , 2021, 30, 096120332110138.	0.8	5
7	Pentraxin-3 detected in human saliva shows limited correlation with biomarkers associated with systemic inflammation. <i>Apmis</i> , 2021, 129, 304-313.	0.9	2
8	Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2021, 12, 688753.	2.2	12
9	Plasma C-Reactive Protein and Pentraxin-3 Reference Intervals During Normal Pregnancy. <i>Frontiers in Immunology</i> , 2021, 12, 722118.	2.2	12
10	The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus. <i>Journal of Clinical Medicine</i> , 2021, 10, 5837.	1.0	27
11	Elevated free secretory component in early rheumatoid arthritis and prior to arthritis development in patients at increased risk. <i>Rheumatology</i> , 2020, 59, 979-987.	0.9	4
12	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	3.0	27
13	Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease. <i>Clinical and Experimental Immunology</i> , 2020, 199, 245-254.	1.1	29
14	Presence of salivary IgA anti-citrullinated protein antibodies associate with higher disease activity in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 274.	1.6	15
15	P23...Longitudinal antinuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of swedish cases with recent-onset disease. , 2020, , .		0
16	P106...Pentameric, but not monomeric C-reactive protein, limits the snRNP-immune complex triggered type I interferon response: implications for lupus pathogenesis. , 2020, , .		0
17	C-Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205. <i>Frontiers in Immunology</i> , 2020, 11, 622326.	2.2	26
18	Pronounced Diurnal Pattern of Salivary C-Reactive Protein (CRP) With Modest Associations to Circulating CRP Levels. <i>Frontiers in Immunology</i> , 2020, 11, 607166.	2.2	8

#	ARTICLE	IF	CITATIONS
19	The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts. <i>Lupus</i> , 2019, 28, 1261-1272.	0.8	22
20	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 492-500.	1.0	15
21	264...Damage accrual in swedish systemic lupus erythematosus: secondary sjögrens syndrome is among the factors associated with increased risk. , 2019, , .		0
22	Sex differences in clinical presentation of systemic lupus erythematosus. <i>Biology of Sex Differences</i> , 2019, 10, 60.	1.8	55
23	S2A:6...Soluble urokinase plasminogen activator receptor (supar) predicts the development of organ damage over 5 years in systemic lupus erythematosus: results from the slicc inception cohort. , 2018, , .		0
24	PS4:71...Iga anti-phospholipid antibodies in swedish cases with systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. , 2018, , .		0
25	Active NET formation in Libmanâ€“Sacks endocarditis without antiphospholipid antibodies: A dramatic onset of systemic lupus erythematosus. <i>Autoimmunity</i> , 2018, 51, 310-318.	1.2	11
26	Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. <i>Clinical and Experimental Immunology</i> , 2018, 194, 27-38.	1.1	16
27	Changes in anti-citrullinated protein antibody isotype levels in relation to disease activity and response to treatment in early rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2018, 194, 391-399.	1.1	17
28	Circulating cartilage oligomeric matrix protein in juvenile idiopathic arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 194-197.	0.6	6
29	Interferon-Î± coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 <i>in vitro</i> . <i>Clinical and Experimental Immunology</i> , 2017, 189, 83-91.	1.1	17
30	A single nucleotide polymorphism in the <i>NCF1</i> gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1607-1613.	0.5	103
31	Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE. <i>Lupus Science and Medicine</i> , 2017, 4, e000225.	1.1	18
32	Long-term follow-up in primary Sjögrenâ€™s syndrome reveals differences in clinical presentation between female and male patients. <i>Biology of Sex Differences</i> , 2017, 8, 25.	1.8	39
33	THU0345...Presence of Immunoglobulin (IG) A Antibodies against Cardiolipin and Î²2-Glycoprotein-I in The Absence of IGG and IGM in Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 312.1-312.	0.5	0
34	Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 338.	1.6	27
35	Soluble urokinase plasminogen activator receptorâ€”A valuable biomarker in systemic lupus erythematosus?. <i>Clinica Chimica Acta</i> , 2015, 444, 234-241.	0.5	27
36	Four Anti-dsDNA Antibody Assays in Relation to Systemic Lupus Erythematosus Disease Specificity and Activity. <i>Journal of Rheumatology</i> , 2015, 42, 817-825.	1.0	57

#	ARTICLE	IF	CITATIONS
37	Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 188.	0.8	43
38	Association of Serum C-reactive Protein Levels With Lupus Disease Activity in the Absence of Measurable Interferon- γ and a C-reactive Protein Gene Variant. <i>Arthritis and Rheumatology</i> , 2014, 66, 1568-1573.	2.9	30
39	THU0042...Autoantibodies against High Mobility Group Box Protein-1 in Systemic Lupus Erythematosus: Association with Disease Activity and Other Antinuclear Antibodies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 191.1-191.	0.5	0
40	Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. <i>Translational Research</i> , 2013, 162, 287-296.	2.2	43
41	C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis. <i>Autoimmunity</i> , 2013, 46, 205-214.	1.2	35
42	C1q regulates collagen-dependent production of reactive oxygen species, aggregation and levels of soluble P-selectin in whole blood. <i>Immunology Letters</i> , 2012, 142, 28-33.	1.1	10
43	IgG Rheumatoid Factors Against the Four Human Fc γ Subclasses in Early Rheumatoid Arthritis (The Swedish TIRA Project). <i>Scandinavian Journal of Immunology</i> , 2012, 75, 115-119.	1.3	3
44	Cell expansion of human articular chondrocytes on macroporous gelatine scaffolds—impact of microcarrier selection on cell proliferation. <i>Biomedical Materials (Bristol)</i> , 2011, 6, 065001.	1.7	18
45	Beware of Antibodies to Dietary Proteins in “Antigen-specific” Immunoassays! Falsely Positive Anticytokine Antibody Tests Due to Reactivity with Bovine Serum Albumin in Rheumatoid Arthritis (The Tj ETQq1 1107843146gBT /O		
46	Designed Surface with Tunable IgG Density as an in Vitro Model for Immune Complex Mediated Stimulation of Leukocytes. <i>Langmuir</i> , 2010, 26, 3493-3497.	1.6	2
47	C1q induces a rapid up-regulation of P-selectin and modulates collagen- and collagen-related peptide-triggered activation in human platelets. <i>Immunobiology</i> , 2010, 215, 987-995.	0.8	24
48	Interferon- γ mediates suppression of C-reactive protein: Explanation for muted C-reactive protein response in lupus flares?. <i>Arthritis and Rheumatism</i> , 2009, 60, 3755-3760.	6.7	78
49	Human articular chondrocytes on macroporous gelatin microcarriers form structurally stable constructs with blood-derived biological glues <i>in vitro</i> . <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2009, 3, 450-460.	1.3	35
50	Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. <i>Clinica Chimica Acta</i> , 2009, 400, 128-131.	0.5	17
51	Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. <i>Arthritis Research and Therapy</i> , 2009, 11, R188.	1.6	39
52	Simultaneous use of electrochemistry and chemiluminescence to detect reactive oxygen species produced by human neutrophils. <i>Cell Biology International</i> , 2008, 32, 1486-1496.	1.4	15
53	C-reactive protein and C1q regulate platelet adhesion and activation on adsorbed immunoglobulin G and albumin. <i>Immunology and Cell Biology</i> , 2008, 86, 466-474.	1.0	20
54	Immobilized Chemoattractant Peptides Mediate Adhesion and Distinct Calcium-Dependent Cell Signaling in Human Neutrophils. <i>Langmuir</i> , 2008, 24, 6803-6811.	1.6	12

#	ARTICLE	IF	CITATIONS
55	Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRP-C1q interaction. <i>Biochemical and Biophysical Research Communications</i> , 2007, 352, 251-258.	1.0	35
56	Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins. <i>Clinica Chimica Acta</i> , 2007, 378, 13-23.	0.5	48
57	Surface plasmon resonance detection of blood coagulation and platelet adhesion under venous and arterial shear conditions. <i>Biosensors and Bioelectronics</i> , 2007, 23, 261-268.	5.3	27
58	Tu-P10:452 C-reactive protein inhibit complement-mediated platelet activation suggesting a protective role in atherogenesis. <i>Atherosclerosis Supplements</i> , 2006, 7, 284.	1.2	0
59	Electrochemical characterization and application of azurin-modified gold electrodes for detection of superoxide. <i>Biosensors and Bioelectronics</i> , 2006, 22, 213-219.	5.3	22
60	Role of the actin cytoskeleton during respiratory burst in chemoattractant-stimulated neutrophils. <i>Cell Biology International</i> , 2006, 30, 154-163.	1.4	39
61	Whole blood coagulation on protein adsorption-resistant PEG and peptide functionalised PEG-coated titanium surfaces. <i>Biomaterials</i> , 2005, 26, 861-872.	5.7	140
62	Oxygen radical production in neutrophils interacting with platelets and surface-immobilized plasma proteins: Role of tyrosine phosphorylation. <i>Journal of Biomedical Materials Research - Part A</i> , 2003, 67A, 439-447.	2.1	22
63	Interactions between surface-bound actin and complement, platelets, and neutrophils. <i>Journal of Biomedical Materials Research - Part A</i> , 2003, 66A, 162-175.	2.1	19
64	Platelets stimulated by IgG-coated surfaces bind and activate neutrophils through a selectin-dependent pathway. <i>Biomaterials</i> , 2003, 24, 1559-1573.	5.7	28
65	On the binding of complement to solid artificial surfaces in vitro. <i>Biomaterials</i> , 2002, 23, 981-991.	5.7	53
66	The influence of plasma proteins and platelets on oxygen radical production and F-actin distribution in neutrophils adhering to polymer surfaces. <i>Biomaterials</i> , 2002, 23, 1785-1795.	5.7	56
67	C1q-independent activation of neutrophils by immunoglobulin M-coated surfaces. <i>Journal of Biomedical Materials Research Part B</i> , 2001, 57, 550-558.	3.0	23
68	Complement activation on immunoglobulin G-coated hydrophobic surfaces enhances the release of oxygen radicals from neutrophils through an actin-dependent mechanism. <i>Journal of Biomedical Materials Research Part B</i> , 2000, 51, 742-751.	3.0	36